Recipharm makes strategic investment in Synthonics and partners in development of novel compounds

SWEDEN


Recipharm today announces that it has made an equity investment in Synthonics
Inc and purchased $2.0 million of preferred stock in the company.
A further $2.0 million of preferred stock will be purchased upon Synthonics’
achievement of certain milestones, which could be expected during 2016.  In
addition, Synthonics and Recipharm have entered into a Joint Development
Agreement under which Synthonics gains access to Recipharm’s expertise in drug
development, marketing and manufacturing in exchange for a royalty payment on
certain of Synthonics’ compounds. Synthonics has developed a unique drug
delivery technology for metal coordination of pharmaceutical APIs. In connection
with its investment, Recipharm’s Carl-Johan Spak has joined Synthonics’ board of
directors.

Ken Slepicka, CEO of Synthonics, said: “Synthonics is delighted to extend the
partnership with Recipharm to help advance promising molecules to market. We are
very impressed with Recipharm’s formulation and development teams and expect
this agreement and financial support to help us further advance several of our
current projects to commercialisation.

Carl-Johan Spak, Executive Vice President, Technology and Development,
commented: “This transaction expands our footprint within the US and builds upon
our existing Joint Marketing Agreement with Synthonics.  In addition, it gives
us an opportunity to share in the upside of Synthonics’ chemistry, which we
believe offers an elegant and cost-effective means to create patentable drugs
that address difficult absorption and delivery issues. We believe that this
collaboration will enhance our ability to serve our customers with exciting drug
delivery solutions.”
For more information please visit www.recipharm.com or contact:
Thomas Eldered, CEO Recipharm, thomas.eldered@recipharm.com, + 46 8 6025210
Carl-Johan Spak, EVP Development & Technology, carl-johan.spak@recipharm.com,
+46 8 6025 313
Ken Slepicka, CEO Synthonics, kslepicka@synthonicsinc.com, +1 708-209-1907

This information is published in accordance with the Swedish Securities Market
Act, the Swedish Financial Instruments Trading Act and/or the regulations of
NASDAQ Stockholm. This information was submitted for publication on 14 April
2015, at 10:00 am CET.

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing
Organisation) in the pharmaceutical industry employing some 2,200 employees.
Recipharm offers manufacturing services of pharmaceuticals in various dosage
forms, production of clinical trial material including API and pharmaceutical
product development. Recipharm manufactures more than 400 different products to
customers ranging from Big Pharma to smaller research- and development
companies. Recipharm’s turnover is approximately SEK 3.3 billion and the Company
operates development and manufacturing facilities in Sweden, France, the UK,
Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The
Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.

For more information on Recipharm and our services, please visit
www.recipharm.com

About Synthonics
Synthonics, Inc. is a specialty pharmaceutical company focused on the discovery,
development and licensing of patent-protected drugs (metal coordinated
pharmaceuticals or “MCPs”) that incorporate its proprietary metal coordination
chemistry. MCPs have a profound effect on a variety of pharmacokinetic
parameters including improved absorption, reduced toxicity, more reliable
dosing, modified release and targeted delivery.

For more information visit www.synthonicsinc.com
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52
00, Fax 46 8 81 87 03
www.recipharm.com

Attachments

04133617.pdf